RxDoctor Payments Data

Eric Marom

Internal Medicine · Columbia, SCNPI 1942512173

Payments from drug & device makers

$400in general payments, 2019–2025

Across 22 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$90
  • Pfizer$64
  • Sanofi-aventis U.S. LLC$55
  • AbbVie$52
  • Dexcom, Inc.$34
  • Abbott$32
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$400 in reported general payments places this provider in the 50th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$338,455
Medicare patients
607
Services billed
6,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin190$223,661
EliquisApixaban119$121,637
OzempicSemaglutide49$70,393
MounjaroTirzepatide56$69,683
EntrestoSacubitril/Valsartan53$68,688
RybelsusSemaglutide63$66,723
XareltoRivaroxaban35$44,252
JanuviaSitagliptin Phosphate27$39,911
FarxigaDapagliflozin Propanediol22$30,921
LinzessLinaclotide15$23,358
MyrbetriqMirabegron27$22,037
Humalog Kwikpen U-200Insulin Lispro12$20,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$13,791
Repatha SureclickEvolocumab19$12,584
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$10,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$90$137,116112 claims
PfizerEliquis$64$121,637119 claims
NovartisEntresto$19$68,68853 claims
Johnson & JohnsonXarelto$13$44,25235 claims
AstraZenecaFarxiga, Breztri Aerosphere$27$37,89234 claims
AbbVieLinzess$52$23,35815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →